109 related articles for article (PubMed ID: 38805937)
1. Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.
Ma S; Long G; Jiang Z; Zhang Y; Sun L; Pan Y; You Q; Guo X
Eur J Med Chem; 2024 Aug; 274():116532. PubMed ID: 38805937
[TBL] [Abstract][Full Text] [Related]
2. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
Rogawski DS; Grembecka J; Cierpicki T
Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
[TBL] [Abstract][Full Text] [Related]
3. Histone lysine methyltransferases as anti-cancer targets for drug discovery.
Liu Q; Wang MW
Acta Pharmacol Sin; 2016 Sep; 37(10):1273-1280. PubMed ID: 27397541
[TBL] [Abstract][Full Text] [Related]
4. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
Zagni C; Chiacchio U; Rescifina A
Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
[TBL] [Abstract][Full Text] [Related]
5. The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications.
Li Y; Ge K; Li T; Cai R; Chen Y
Protein Cell; 2023 Apr; 14(3):165-179. PubMed ID: 37051671
[TBL] [Abstract][Full Text] [Related]
6. Understanding histone H3 lysine 36 methylation and its deregulation in disease.
Li J; Ahn JH; Wang GG
Cell Mol Life Sci; 2019 Aug; 76(15):2899-2916. PubMed ID: 31147750
[TBL] [Abstract][Full Text] [Related]
7. Targeting histone lysine methylation in cancer.
McGrath J; Trojer P
Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
[TBL] [Abstract][Full Text] [Related]
8. Understanding the language of Lys36 methylation at histone H3.
Wagner EJ; Carpenter PB
Nat Rev Mol Cell Biol; 2012 Jan; 13(2):115-26. PubMed ID: 22266761
[TBL] [Abstract][Full Text] [Related]
9. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic small molecule modulators of histone and DNA methylation.
Hauser AT; Robaa D; Jung M
Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Shrestha A; Kim N; Lee SJ; Jeon YH; Song JJ; An H; Cho SJ; Kadayat TM; Chin J
J Med Chem; 2021 Oct; 64(20):14913-14929. PubMed ID: 34488340
[TBL] [Abstract][Full Text] [Related]
12. Amide-derived lysine analogues as substrates and inhibitors of histone lysine methyltransferases and acetyltransferases.
Hintzen JCJ; Merx J; Maas MN; Langens SGHA; White PB; Boltje TJ; Mecinović J
Org Biomol Chem; 2021 Dec; 20(1):173-181. PubMed ID: 34877957
[TBL] [Abstract][Full Text] [Related]
13. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
[TBL] [Abstract][Full Text] [Related]
15. The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
Berthelet J; Michail C; Bui LC; Le Coadou L; Sirri V; Wang L; Dulphy N; Dupret JM; Chomienne C; Guidez F; Rodrigues-Lima F
Mol Pharmacol; 2021 Sep; 100(3):283-294. PubMed ID: 34266924
[TBL] [Abstract][Full Text] [Related]
16. SET DOMAIN GROUP 708, a histone H3 lysine 36-specific methyltransferase, controls flowering time in rice (Oryza sativa).
Liu B; Wei G; Shi J; Jin J; Shen T; Ni T; Shen WH; Yu Y; Dong A
New Phytol; 2016 Apr; 210(2):577-88. PubMed ID: 26639303
[TBL] [Abstract][Full Text] [Related]
17. Allosteric regulation of histone lysine methyltransferases: from context-specific regulation to selective drugs.
Davidovich C; Zhang Q
Biochem Soc Trans; 2021 Apr; 49(2):591-607. PubMed ID: 33769454
[TBL] [Abstract][Full Text] [Related]
18. Histone H2A ubiquitination inhibits the enzymatic activity of H3 lysine 36 methyltransferases.
Yuan G; Ma B; Yuan W; Zhang Z; Chen P; Ding X; Feng L; Shen X; Chen S; Li G; Zhu B
J Biol Chem; 2013 Oct; 288(43):30832-42. PubMed ID: 24019522
[TBL] [Abstract][Full Text] [Related]
19. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
20. Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.
Bhat KP; Ümit Kaniskan H; Jin J; Gozani O
Nat Rev Drug Discov; 2021 Apr; 20(4):265-286. PubMed ID: 33469207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
